Y Intercept Hong Kong Ltd Buys 26,310 Shares of Progyny, Inc. $PGNY

Y Intercept Hong Kong Ltd lifted its stake in Progyny, Inc. (NASDAQ:PGNY) by 88.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,196 shares of the company’s stock after buying an additional 26,310 shares during the period. Y Intercept Hong Kong Ltd owned about 0.07% of Progyny worth $1,236,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. New York State Teachers Retirement System lifted its stake in shares of Progyny by 0.7% in the first quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock valued at $1,635,000 after buying an additional 500 shares during the period. Leibman Financial Services Inc. raised its position in Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock worth $1,011,000 after purchasing an additional 513 shares in the last quarter. Polen Capital Management LLC raised its position in Progyny by 0.3% in the first quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock worth $5,842,000 after purchasing an additional 798 shares in the last quarter. Militia Capital Partners LP raised its position in Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Invesco Ltd. raised its position in Progyny by 0.4% in the first quarter. Invesco Ltd. now owns 275,936 shares of the company’s stock worth $6,164,000 after purchasing an additional 1,117 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Trading Down 1.5%

NASDAQ PGNY opened at $18.43 on Tuesday. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 31.24, a PEG ratio of 1.59 and a beta of 1.29. The company has a 50 day moving average of $21.21 and a 200-day moving average of $21.91. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $26.76.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The company had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the sale, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 7,895 shares of company stock valued at $179,311. 9.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on PGNY. Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. Raymond James Financial set a $28.00 target price on shares of Progyny in a research report on Friday, August 8th. Canaccord Genuity Group increased their target price on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 target price (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.